Binimetinib (MEK162, ARRY-162, ARRY-438162, MEK-162, ARRY162, ARRY438162)，又称贝美替尼，是可口服的MEK1/2抑制剂，IC₅₀为12 nM，通过抑制MEK1/2下游信号传导来抑制肿瘤细胞增殖，临床上常用于治疗具有BRAF V600E或V600K突变的转移性黑色素瘤患者。

参考文献

[1] J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794.

[2] D Wright, et al. 2009, Arraybiopharma. Abstract FRI0063.

[3] Serra V, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013 Jun;123(6):2551-63.

[4] Cheng H, et al. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35(23):2961-70.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。